Xilio Therapeutics (NASDAQ:XLO) Shares Up 1%

Xilio Therapeutics, Inc. (NASDAQ:XLO)’s stock price shot up 1% during trading on Wednesday . The stock traded as high as $1.11 and last traded at $1.06. 297,031 shares traded hands during trading, a decline of 72% from the average session volume of 1,045,277 shares. The stock had previously closed at $1.05.

Xilio Therapeutics Stock Performance

The company has a market capitalization of $36.54 million, a PE ratio of -0.38 and a beta of -0.12. The company’s 50-day simple moving average is $0.90 and its 200-day simple moving average is $1.03.

Insiders Place Their Bets

In other news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were acquired at an average price of $0.76 per share, with a total value of $368,790.00. Following the completion of the acquisition, the insider now directly owns 7,345,473 shares in the company, valued at $5,582,559.48. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.60% of the stock is currently owned by insiders.

Institutional Trading of Xilio Therapeutics

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC bought a new position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned 0.09% of Xilio Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.